Clinical review 130: Addison's disease 2001

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 7, 2001, Pages 2909-2922

  Ten, Svetlana ^a   New, Maria ^a   Maclaren, Noel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MINERALOCORTICOID;

ADDISON DISEASE; DIAGNOSTIC APPROACH ROUTE; GENDER; GENETIC DISORDER; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ADDISON DISEASE; FEMALE; HUMANS; MALE;

EID: 0034918704     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.7.2909     Document Type: Review

References (84)

1. The prevalence of Addison's disease in Coventry, UK
2. White Addison's disease: What is the possible cause?
3. Dax-1 as one of the target genes of Ad4BP/SF-1
4. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita
5. ACTH resistance syndromes
6. Expression of DAX-1, the gene responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis
7. A cell-specific nuclear receptor plays essential roles in adrenal and gonadal development
8. Inherited congenital adrenal hyperplasia in the rabbit: Absent cholesterol side-chain cleavage cytochrome P450 gene expression
9. A cell-specific nuclear receptor regulates the steroid hydroxylases
10. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans
11. Apparently normal ovarian. Differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency
12. Coal-black hyperpigmentation at birth in a child with congenital adrenal hypoplasia
13. Congenital adrenal hypoplasia and selective absence of pituitary luteinizing hormone: A new autosomal recessive syndrome
14. Clinical and functional effects of mutations in the DAX-1 gene in patients with adrenal hypoplasia congenita
15. Isolated and contiguous glycerol kinase gene disorders: A review
16. Active hypothalamic-pituitary-gonadal axis in an infant with X-linked adrenal hypoplasia congenita
17. Prolonged activation of the hypothalamus-pituitary-gonadal axis in a child with X-linked adrenal hypoplasia congenita
18. Congenital adrenal hypoplasia: Clinical spectrum, experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene
19. Minipuberty of infancy and adolescent pubertal function in adrenal hypoplasia congenita
20. Hypogonadotropic hypogonadism in a female caused by an X-linked recessive mutation in the DAX1 gene
21. Polyglandular autoimmune syndrome type I among Iranian Jews
22. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients
23. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients
24. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes
25. Autoimmunity and diabetes
26. Adrenal dysfunction in asymptomatic patients with adrenocortical autoantibodies
27. Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers
28. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease
29. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease
30. Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17 α-hydroxylase
31. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease
32. Positional cloning of the APECED gene
33. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains
34. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients
35. The human leukocyte antigen HLA DRB3*020/DQA1*0501 haplotype is associated with Graves' disease in African Americans
36. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis and therapy
37. A mouse model for X-linked adrenoleukodystrophy
38. The prenatal diagnosis of X-linked adrenoleukodystrophy
39. Lovastatin therapy for X-linked adrenoleukodystrophy: Clinical and biochemical observations on 12 patients
40. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): Implications for therapy
41. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy
42. Retroviral transfer and long-term expression of the adrenoleukodystrophy gene in human CD34+ cells
43. Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
44. Primary adrenal insufficiency in patients with the acquired immunodeficiency syndrome: A report of five cases
45. Reversal of adrenal glucocorticoid dysfunction in a patient with disseminated histoplasmosis
46. Disseminated cryptococcosis in an apparently normal host presenting as primary adrenal insufficiency: Diagnosis by fine needle aspiration
47. Septicemic adrenal hemorrhage
48. Definitive adrenal insufficiency due to bilateral adrenal hemorrhage and primary antiphospholipid syndrome
49. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
50. Mutations in the steroidogenic acute regulatory protein (StAR) in six patients with congenital lipoid adrenal hyperplasia
51. Oxidative phosphorylation defect associated with primary adrenal insufficiency
52. Identification of a large-scale mitochondrial deoxyribonucleic acid deletion in endocrinopathies and deafness: Report of two unrelated cases with diabetes mellitus and adrenal insufficiency, respectively
53. Primary adrenal insufficiency in a child with a mitochondrial DNA deletion
54. Mitochondrial DNA deletion with Kearns Sayre syndrome in a child with Addison disease
55. Multiple endocrine involvement in two pediatric patients with Kearns-Sayre syndrome
56. Adrenal cortical function in homozygous familial hypercholesterolemia
57. Adrenal insufficiency in Smith-Lemli-Opitz syndrome
58. Effects of aminoglutethimide on adrenal steroid secretion
59. Inhibition of adrenal steroidogenesis by the anesthetic etomidate
60. The use of ketoconazole as an inhibitor of steroid production
61. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11β-hydroxalation
62. Suramin and function of the adrenal cortex
63. Effects of some clinically encountered drugs on steroid synthesis and degradation
64. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis
65. Cortisol production rate in childhood and adolescence
66. Cyclic vomiting syndrome: The corticotropin-releasing-factor hypothesis
67. Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy
68. Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement
69. Cushing's disease without hypercortisolism
70. Probable pituitary adenoma with adrenocorticotropin hypersecretion (corticotropinoma) secondary to Addison's disease
71. The pituitary gland in untreated Addison's disease. A histologic and immunocytologic study of 18 adenohypophyses
72. Pituitary enlargement associated with Addison's disease
73. Histopathology of the pituitary
74. A possible ACTH secreting tumour of the pituitary developing in a conventionally treated case of Addison's disease
75. ACTH-producing pituitary adenomas in Addison's disease: Two cases treated by transsphenoidal microsurgery
76. Hyper-adrenocorticotropinemia in a patient with Addison's disease after treatment with corticosteroids
77. Corticosteroid-binding globulin modulates cortisol concentration responses to a given production rate
78. Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency
79. Glucocorticoid replacement therapy: Are patients over treated and does it matter?
80. Increasing need for replacement therapy in long-standing Addison's disease
81. Mineralocorticoids in congenital adrenal hyperplasia
82. Should we monitor more closely the dosage of 9 α-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia?
83. Corticosteroid therapy in severe illness